The fragment and the protein
Thymosin beta-4 is a 43-residue protein present in most cells, best known for binding actin and regulating how the cytoskeleton is assembled. TB-500 corresponds to a short stretch of that protein, usually described as the part responsible for binding actin.
Suppliers use the two names interchangeably. They are not the same molecule, and a certificate that names one when you ordered the other is telling you something worth noticing.
The consequence is analytical rather than semantic. A short fragment and a 43-residue protein look nothing alike on a mass spectrum, so identity here is not a matter of trust but something a laboratory settles directly. The sequence record for the parent is public, the UniProt entry is the usual reference, and what a certificate of analysis actually reports is where you check whether that comparison was ever made.
Actin, and why it matters for repair
Actin is the structural protein cells use to change shape and move. Anything that regulates its assembly touches cell migration, which is a basic requirement for tissue repair: cells have to reach the site before they can do anything there.
That is the mechanistic argument for the compound. The published work sits mainly in animal models of cardiac, corneal and dermal injury, and it is reasonably consistent in what it reports.
If you searched for what is tb-500 and were handed thymosin beta-4 as the answer, you have already met the central confusion of this corner of the field. Searching the literature filed under the parent protein returns most of the primary work, because that is the label the original research groups publish under.
| Relationship | Fragment of thymosin beta-4 |
| Parent protein | 43 amino acids |
| Proposed mechanism | Actin binding, cell migration |
| Research focus | Cardiac, corneal and dermal injury models |
| Format | Pre-filled peptide pen |
| Purity | ≥ 99% (HPLC) |
| Human trials | None published |
| Category | Research use only |
Product facts. Effect claims are a separate matter and not made here.
Why it is paired with BPC-157
The two are almost always discussed together, and the reasoning is that they act through different routes: one on cell migration, the other on vascular supply and growth factor signalling.
That is a hypothesis about complementarity, not a demonstrated synergy. No controlled work we are aware of tests the combination against either compound alone in a way that would settle it.
There is a related trap in how the material itself gets judged. A high purity figure describes how much of a sample is one substance; it says nothing whatever about which substance that is, and the two questions are answered by different sections of the same document. Why purity alone is not enough takes that apart properly.
What the TB-500 literature does not reach
The animal work is reasonably consistent inside its own models, and that consistency is often read as more than it is. Cardiac, corneal and dermal injury models each interrogate one tissue under one set of conditions. Agreement between them tells you an observation reproduces; it does not tell you it generalises to another species, another injury or another timescale.
The second absence is regulatory. No approval exists anywhere for this fragment and no pharmacopoeial monograph defines what an acceptable batch looks like, so the standard the material is held to is whichever one the supplier elects to apply. That is a reason to read batch documentation closely rather than a reason to assume the worst of everyone selling it.
Anyone competing under anti-doping rules should treat the compound as caught. Fragments in this family fall inside the same category as the parent protein, and the way the prohibited list is drawn works by mechanism rather than by name, which is precisely what makes an unnamed fragment a poor bet.
TB-500 in the catalogue
No batch is released under 99% by HPLC, and each carries its own paperwork.
Where TB-500 fits in
Three pages worth having read before you order.
About TB-500
Questions from our inbox, answered without spin.